Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Nancy Dawson, MD discusses PSA dynamics: the significance of PSA levels and PSA doubling time—the marker which currently provides the most information—and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.